Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience
Advanced Parkinson’s Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually become unpredictable, in part due to erratic gastric absorption and short half of oral levodopa. Attempts to manage such fluctuations with oral dopam...
Uloženo v:
| Vydáno v: | Scientific reports Ročník 13; číslo 1; s. 18681 - 8 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
31.10.2023
Nature Publishing Group Nature Portfolio |
| Témata: | |
| ISSN: | 2045-2322, 2045-2322 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Advanced Parkinson’s Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually become unpredictable, in part due to erratic gastric absorption and short half of oral levodopa. Attempts to manage such fluctuations with oral dopaminergic drugs often lead to disabling dyskinesias. Continuous Subcutaneous Apomorphine Infusion (CSAI), despite being approved for the treatment of APD since 1993, was approved in India only in 2019. We studied the safety, tolerability and efficacy of CSAI in Indian patients with APD in a registry design to raise local awareness of this important treatment. We conducted a prospective registry-based observational audit at 10 centers across different states of India. Patients with APD, not responding to or with significant side effects from oral dopaminergic therapy, were assessed at baseline and at month 6 and 12 following CSAI infusion. Fifty-one patients completed the study, CSAI significantly reduced the functional impact of dyskinesia (p < 0.01 at 6 months and p < 0.001 at 12 months). There was a significant improvement in the OFF-state from baseline (p < 0.01 at 6 months and p < 0.001 at 12 months) No discernible side effects were observed apart from mild site reaction (n = 7), nausea (n = 7) skin nodules (n = 2). CSAI demonstrated safety, efficacy, tolerability and improved quality of life in patients with APD, as shown in previous studies. Our study highlighted current existing inequalities in treatment availability, lack of awareness, knowledge gap, affordability and cost remains a concern regarding apomorphine use in Indian PD population. |
|---|---|
| AbstractList | Advanced Parkinson’s Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually become unpredictable, in part due to erratic gastric absorption and short half of oral levodopa. Attempts to manage such fluctuations with oral dopaminergic drugs often lead to disabling dyskinesias. Continuous Subcutaneous Apomorphine Infusion (CSAI), despite being approved for the treatment of APD since 1993, was approved in India only in 2019. We studied the safety, tolerability and efficacy of CSAI in Indian patients with APD in a registry design to raise local awareness of this important treatment. We conducted a prospective registry-based observational audit at 10 centers across different states of India. Patients with APD, not responding to or with significant side effects from oral dopaminergic therapy, were assessed at baseline and at month 6 and 12 following CSAI infusion. Fifty-one patients completed the study, CSAI significantly reduced the functional impact of dyskinesia (p < 0.01 at 6 months and p < 0.001 at 12 months). There was a significant improvement in the OFF-state from baseline (p < 0.01 at 6 months and p < 0.001 at 12 months) No discernible side effects were observed apart from mild site reaction (n = 7), nausea (n = 7) skin nodules (n = 2). CSAI demonstrated safety, efficacy, tolerability and improved quality of life in patients with APD, as shown in previous studies. Our study highlighted current existing inequalities in treatment availability, lack of awareness, knowledge gap, affordability and cost remains a concern regarding apomorphine use in Indian PD population. Advanced Parkinson’s Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually become unpredictable, in part due to erratic gastric absorption and short half of oral levodopa. Attempts to manage such fluctuations with oral dopaminergic drugs often lead to disabling dyskinesias. Continuous Subcutaneous Apomorphine Infusion (CSAI), despite being approved for the treatment of APD since 1993, was approved in India only in 2019. We studied the safety, tolerability and efficacy of CSAI in Indian patients with APD in a registry design to raise local awareness of this important treatment. We conducted a prospective registry-based observational audit at 10 centers across different states of India. Patients with APD, not responding to or with significant side effects from oral dopaminergic therapy, were assessed at baseline and at month 6 and 12 following CSAI infusion. Fifty-one patients completed the study, CSAI significantly reduced the functional impact of dyskinesia (p < 0.01 at 6 months and p < 0.001 at 12 months). There was a significant improvement in the OFF-state from baseline (p < 0.01 at 6 months and p < 0.001 at 12 months) No discernible side effects were observed apart from mild site reaction (n = 7), nausea (n = 7) skin nodules (n = 2). CSAI demonstrated safety, efficacy, tolerability and improved quality of life in patients with APD, as shown in previous studies. Our study highlighted current existing inequalities in treatment availability, lack of awareness, knowledge gap, affordability and cost remains a concern regarding apomorphine use in Indian PD population. Abstract Advanced Parkinson’s Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually become unpredictable, in part due to erratic gastric absorption and short half of oral levodopa. Attempts to manage such fluctuations with oral dopaminergic drugs often lead to disabling dyskinesias. Continuous Subcutaneous Apomorphine Infusion (CSAI), despite being approved for the treatment of APD since 1993, was approved in India only in 2019. We studied the safety, tolerability and efficacy of CSAI in Indian patients with APD in a registry design to raise local awareness of this important treatment. We conducted a prospective registry-based observational audit at 10 centers across different states of India. Patients with APD, not responding to or with significant side effects from oral dopaminergic therapy, were assessed at baseline and at month 6 and 12 following CSAI infusion. Fifty-one patients completed the study, CSAI significantly reduced the functional impact of dyskinesia (p < 0.01 at 6 months and p < 0.001 at 12 months). There was a significant improvement in the OFF-state from baseline (p < 0.01 at 6 months and p < 0.001 at 12 months) No discernible side effects were observed apart from mild site reaction (n = 7), nausea (n = 7) skin nodules (n = 2). CSAI demonstrated safety, efficacy, tolerability and improved quality of life in patients with APD, as shown in previous studies. Our study highlighted current existing inequalities in treatment availability, lack of awareness, knowledge gap, affordability and cost remains a concern regarding apomorphine use in Indian PD population. Advanced Parkinson's Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually become unpredictable, in part due to erratic gastric absorption and short half of oral levodopa. Attempts to manage such fluctuations with oral dopaminergic drugs often lead to disabling dyskinesias. Continuous Subcutaneous Apomorphine Infusion (CSAI), despite being approved for the treatment of APD since 1993, was approved in India only in 2019. We studied the safety, tolerability and efficacy of CSAI in Indian patients with APD in a registry design to raise local awareness of this important treatment. We conducted a prospective registry-based observational audit at 10 centers across different states of India. Patients with APD, not responding to or with significant side effects from oral dopaminergic therapy, were assessed at baseline and at month 6 and 12 following CSAI infusion. Fifty-one patients completed the study, CSAI significantly reduced the functional impact of dyskinesia (p < 0.01 at 6 months and p < 0.001 at 12 months). There was a significant improvement in the OFF-state from baseline (p < 0.01 at 6 months and p < 0.001 at 12 months) No discernible side effects were observed apart from mild site reaction (n = 7), nausea (n = 7) skin nodules (n = 2). CSAI demonstrated safety, efficacy, tolerability and improved quality of life in patients with APD, as shown in previous studies. Our study highlighted current existing inequalities in treatment availability, lack of awareness, knowledge gap, affordability and cost remains a concern regarding apomorphine use in Indian PD population.Advanced Parkinson's Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually become unpredictable, in part due to erratic gastric absorption and short half of oral levodopa. Attempts to manage such fluctuations with oral dopaminergic drugs often lead to disabling dyskinesias. Continuous Subcutaneous Apomorphine Infusion (CSAI), despite being approved for the treatment of APD since 1993, was approved in India only in 2019. We studied the safety, tolerability and efficacy of CSAI in Indian patients with APD in a registry design to raise local awareness of this important treatment. We conducted a prospective registry-based observational audit at 10 centers across different states of India. Patients with APD, not responding to or with significant side effects from oral dopaminergic therapy, were assessed at baseline and at month 6 and 12 following CSAI infusion. Fifty-one patients completed the study, CSAI significantly reduced the functional impact of dyskinesia (p < 0.01 at 6 months and p < 0.001 at 12 months). There was a significant improvement in the OFF-state from baseline (p < 0.01 at 6 months and p < 0.001 at 12 months) No discernible side effects were observed apart from mild site reaction (n = 7), nausea (n = 7) skin nodules (n = 2). CSAI demonstrated safety, efficacy, tolerability and improved quality of life in patients with APD, as shown in previous studies. Our study highlighted current existing inequalities in treatment availability, lack of awareness, knowledge gap, affordability and cost remains a concern regarding apomorphine use in Indian PD population. |
| ArticleNumber | 18681 |
| Author | Rodriguez-Blazquez, Carmen Chaudhuri, Kallol Ray Falup-Pecurariu, Cristian Metta, Vinod Borgohain, Rupam Goyal, Vinay L.K., Prashanth Kumar, Natuva Sai Sampath Dhamija, Rajinder K. Mrudula, Rukmini Kumar, Suresh S., Arunan Batzu, Lucia Bhattacharya, Kalyan |
| Author_xml | – sequence: 1 givenname: Vinod surname: Metta fullname: Metta, Vinod email: vinod.metta@nhs.net organization: Department of Neurosciences, Institute of Psychiatry, Psychology and Neuroscience and Parkinson’s Foundation Centre of Excellence, King’s College London, King’s College Hospital, Parkinson’s Foundation Centre of Excellence, King’s College Hospital, London, Parkinson’s Foundation Centre of Excellence, King’s College Hospital London – sequence: 2 givenname: Rajinder K. surname: Dhamija fullname: Dhamija, Rajinder K. organization: Institute of Human Behavior and Allied Sciences, Lady Hardinge Medical College and SSK Hospital – sequence: 3 givenname: Lucia surname: Batzu fullname: Batzu, Lucia organization: Department of Neurosciences, Institute of Psychiatry, Psychology and Neuroscience and Parkinson’s Foundation Centre of Excellence, King’s College London, King’s College Hospital, Parkinson’s Foundation Centre of Excellence, King’s College Hospital, London – sequence: 4 givenname: Rukmini surname: Mrudula fullname: Mrudula, Rukmini organization: Institute of Movement Disorders, Narayana Medical College and Postgraduate Research Centre, Nizams Institute of Medical Sciences – sequence: 5 givenname: Natuva Sai Sampath surname: Kumar fullname: Kumar, Natuva Sai Sampath organization: Institute of Movement Disorders, Narayana Medical College and Postgraduate Research Centre – sequence: 6 givenname: Arunan surname: S. fullname: S., Arunan organization: SRM Institute of Medical Sciences and Technology – sequence: 7 givenname: Cristian surname: Falup-Pecurariu fullname: Falup-Pecurariu, Cristian organization: Department of Neurology, Transilvania University of Brasov – sequence: 8 givenname: Carmen surname: Rodriguez-Blazquez fullname: Rodriguez-Blazquez, Carmen organization: Carlos 111, Health Institute – sequence: 9 givenname: Vinay surname: Goyal fullname: Goyal, Vinay organization: Institute of Movement Disorders and Parkinson’s Centre, Medanta Hospital – sequence: 10 givenname: Prashanth surname: L.K. fullname: L.K., Prashanth organization: Center for Parkinson’s Disease and Movement Disorders, Manipal Hospital – sequence: 11 givenname: Kalyan surname: Bhattacharya fullname: Bhattacharya, Kalyan organization: R G Kar Medical College and Hospital – sequence: 12 givenname: Suresh surname: Kumar fullname: Kumar, Suresh organization: Amrita Institute of Medical Sciences – sequence: 13 givenname: Kallol Ray surname: Chaudhuri fullname: Chaudhuri, Kallol Ray organization: Department of Neurosciences, Institute of Psychiatry, Psychology and Neuroscience and Parkinson’s Foundation Centre of Excellence, King’s College London, King’s College Hospital, Parkinson’s Foundation Centre of Excellence, King’s College Hospital, London – sequence: 14 givenname: Rupam surname: Borgohain fullname: Borgohain, Rupam organization: Nizams Institute of Medical Sciences |
| BookMark | eNp9kk1v1DAQhiNUREvpH-BkiQPlEBh_bRIuqCpfK1W0EnC2Js5k6yWxFzup6B_gd-PtFkF7qA8ey37fxzP2PC32fPBUFM85vOYg6zdJcd3UJQhZqgVAnh8VBwKULoUUYu-_9X5xlNIa8tCiUbx5UuzLqoFqUTUHxe-v2NN0zdB3bAoDRWzd4PJG6NkQ_KqcKI4MN2EMcXPpPDHn-zm54POCYXeF3lLHLjD-cD4F_zKxziXCRG8zky1953IY52FypSWfaez45OK8XH55_4rRrw1FR5nwrHjc45Do6DYeFt8_fvh2-rk8O_-0PD05K63m9VRK21vQvNUdb3quOi57gULLBfC2qZCqCjRwkqi4so2yNVkNbdMCksZctDwsljtuF3BtNtGNGK9NQGduNkJcGYyTswOZurYVWgLZAVdIbQu6J65alKC1RJFZ73aszdyO1G2rizjcgd498e7SrMKV4bDgtRBVJhzfEmL4OVOazOiSpWFAT2FORtS1zt8IizpLX9yTrsMcfX6rrUppqDjwrKp3KhtDSpF6Y92EU_6tnIAb8s1m2zxm1zwmN4-5aR6jslXcs_4t5EGT3JlSFvsVxX9ZPeD6AxlF1_o |
| CitedBy_id | crossref_primary_10_1016_j_parkreldis_2025_107872 crossref_primary_10_1016_j_molstruc_2025_142574 |
| Cites_doi | 10.1007/s40268-018-0230-3 10.1371/journal.pone.0136541 10.1002/mds.29410 10.1097/WNF.0000000000000082 10.14802/jmd.09002 10.1007/s00702-013-0981-5 10.1038/s41531-021-00194-7 10.1007/s40263-019-00661-z 10.1016/S1474-4422(18)30295-3 10.1002/mds.21596 10.3389/fneur.2020.00524 10.1212/WNL.17.5.427 10.1002/mdc3.12350 10.1002/mds.26067 10.1007/s00702-023-02609-6 10.1093/occmed/kqu024 10.1080/08870449708406741 10.4103/AOMD.AOMD_16_20 10.1111/j.1360-0443.1987.tb01479.x 10.1016/j.parkreldis.2016.12.004 10.1590/1980-57642018dn13-010008 10.1371/journal.pone.0195287 10.3390/jpm11070680 10.2147/JMDH.S105857 10.1002/mds.27626 10.1016/j.parkreldis.2015.06.012 10.1136/jnnp.73.6.629 10.1517/13543784.11.2.295 10.1016/j.parkreldis.2016.12.003 10.1002/mds.26270 10.1016/S1474-4422(18)30239-4 10.1016/S1474-4422(06)70373-8 10.1007/s10072-021-05106-4 10.1001/archneur.58.9.1385 10.1016/S0140-6736(88)91193-2 10.1002/brb3.2086 10.1098/rspl.1868.0094 10.1016/j.prdoa.2019.11.004 10.1097/j.pain.0000000000002111 10.1038/s41531-022-00410-y 10.1002/mds.22340 10.1007/s00415-021-10567-w 10.2174/1574886311308010009 10.1017/CBO9781107284210.006 10.1038/s41531-016-0004-y |
| ContentType | Journal Article |
| Copyright | Crown 2023 Crown 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023. Crown. |
| Copyright_xml | – notice: Crown 2023 – notice: Crown 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023. Crown. |
| DBID | C6C AAYXX CITATION 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-023-46003-4 |
| DatabaseName | Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_88c7ace03d014aebb05fe14ba30553a2 PMC10618227 10_1038_s41598_023_46003_4 |
| GeographicLocations | India |
| GeographicLocations_xml | – name: India |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB 7XB 8FK K9. PKEHL PQEST PQUKI Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c518t-3cfc051b5d19f14d13f2a253601b97ae770501e3a414c94c8ec50b9b0ae5a3793 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001123935800094&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Tue Oct 14 19:04:21 EDT 2025 Tue Nov 04 02:06:25 EST 2025 Wed Oct 01 13:51:50 EDT 2025 Tue Oct 07 08:09:22 EDT 2025 Sat Nov 29 06:05:34 EST 2025 Tue Nov 18 21:24:12 EST 2025 Fri Feb 21 02:39:46 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c518t-3cfc051b5d19f14d13f2a253601b97ae770501e3a414c94c8ec50b9b0ae5a3793 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/88c7ace03d014aebb05fe14ba30553a2 |
| PMID | 37907679 |
| PQID | 2884507101 |
| PQPubID | 2041939 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_88c7ace03d014aebb05fe14ba30553a2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10618227 proquest_miscellaneous_2885204068 proquest_journals_2884507101 crossref_citationtrail_10_1038_s41598_023_46003_4 crossref_primary_10_1038_s41598_023_46003_4 springer_journals_10_1038_s41598_023_46003_4 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-10-31 |
| PublicationDateYYYYMMDD | 2023-10-31 |
| PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Metta (CR9) 2020; 3 Lertxundi (CR47) 2013; 8 Trenkwalder (CR8) 2015; 21 Jenner, Katzenschlager (CR34) 2016; 33 Dafsari (CR50) 2019; 34 Chaudhuri, Rizos, Sethi (CR5) 2013; 120 CR32 Dewey, Hutton, LeWitt, Factor (CR46) 2001; 58 Oikonomou (CR11) 2021; 11 Zagnoli (CR51) 2023 Katzenschlager (CR29) 2018; 17 Chaudhuri, Healy, Schapira (CR35) 2006; 5 Djamshidian, Poewe (CR6) 2016; 33 Dorsey (CR3) 2018; 17 Gaire, Kafle, Bastakoti, Paudel, Karki (CR28) 2018; 13 Isaacson (CR44) 2017; 4 Chaudhuri (CR21) 2015; 30 DeMaagd, Philip (CR33) 2015; 40 Schwab, Amador, Lettvin (CR25) 1951; 56 Metta (CR37) 2022; 269 Carbone, Djamshidian, Seppi, Poewe (CR7) 2019; 33 Lawn (CR38) 2021; 162 Matthiessen, Wright (CR22) 1869; 17 Metta (CR4) 2021; 11 Stibe, Lees, Kempster, Stern (CR26) 1988; 1 Marsili, Bologna, Miyasaki, Colosimo (CR48) 2021; 42 Martinez-Martin (CR49) 2015; 30 Auffret, Drapier, Vérin (CR45) 2018; 18 Stern (CR17) 2014; 64 Hoehn, Yahr (CR12) 1967; 17 Goetz (CR14) 2008; 23 Lemere (CR23) 1987; 82 CR10 Bhidayasiri (CR31) 2015; 38 Jenkinson, Fitzpatrick, Peto, Greenhall, Hyman (CR15) 1997; 12 Meira (CR30) 2021; 7 Tai, Lin (CR40) 2020; 2 Antonini (CR36) 2009; 2 Haddad, Pud, Treister, Suzan, Eisenberg (CR43) 2018; 13 Jost (CR13) 2023; 38 CR27 Mulhall (CR24) 2002; 11 Willis (CR1) 2022; 8 Vásquez, Valverde, Aguilar, Gabarain (CR18) 2019; 13 Martinez-Martin (CR39) 2017; 3 Chaudhuri (CR16) 2007; 22 Niimi (CR19) 2019; 5 Valkovic (CR41) 2015; 10 Skogar, Lokk (CR42) 2016; 9 Rajan (CR2) 2020; 11 Chaudhuri (CR20) 2002; 73 46003_CR32 P Martinez-Martin (46003_CR49) 2015; 30 Y Niimi (46003_CR19) 2019; 5 V Metta (46003_CR37) 2022; 269 CG Goetz (46003_CR14) 2008; 23 Y-C Tai (46003_CR40) 2020; 2 M Auffret (46003_CR45) 2018; 18 S Isaacson (46003_CR44) 2017; 4 V Metta (46003_CR4) 2021; 11 F Lemere (46003_CR23) 1987; 82 F Carbone (46003_CR7) 2019; 33 46003_CR27 M Haddad (46003_CR43) 2018; 13 R Rajan (46003_CR2) 2020; 11 U Lertxundi (46003_CR47) 2013; 8 B Meira (46003_CR30) 2021; 7 ER Dorsey (46003_CR3) 2018; 17 CM Stibe (46003_CR26) 1988; 1 HS Dafsari (46003_CR50) 2019; 34 ST Jost (46003_CR13) 2023; 38 KR Chaudhuri (46003_CR35) 2006; 5 P Oikonomou (46003_CR11) 2021; 11 V Metta (46003_CR9) 2020; 3 JP Mulhall (46003_CR24) 2002; 11 G DeMaagd (46003_CR33) 2015; 40 46003_CR10 KR Chaudhuri (46003_CR20) 2002; 73 RB Dewey (46003_CR46) 2001; 58 S Gaire (46003_CR28) 2018; 13 P Jenner (46003_CR34) 2016; 33 F Zagnoli (46003_CR51) 2023 O Skogar (46003_CR42) 2016; 9 MM Hoehn (46003_CR12) 1967; 17 A Matthiessen (46003_CR22) 1869; 17 P Valkovic (46003_CR41) 2015; 10 L Marsili (46003_CR48) 2021; 42 AF Stern (46003_CR17) 2014; 64 A Djamshidian (46003_CR6) 2016; 33 AW Willis (46003_CR1) 2022; 8 A Antonini (46003_CR36) 2009; 2 KR Chaudhuri (46003_CR16) 2007; 22 KR Chaudhuri (46003_CR21) 2015; 30 R Katzenschlager (46003_CR29) 2018; 17 KA Vásquez (46003_CR18) 2019; 13 KR Chaudhuri (46003_CR5) 2013; 120 C Trenkwalder (46003_CR8) 2015; 21 RS Schwab (46003_CR25) 1951; 56 R Bhidayasiri (46003_CR31) 2015; 38 T Lawn (46003_CR38) 2021; 162 P Martinez-Martin (46003_CR39) 2017; 3 C Jenkinson (46003_CR15) 1997; 12 |
| References_xml | – volume: 18 start-page: 91 year: 2018 end-page: 107 ident: CR45 article-title: The many faces of apomorphine: Lessons from the past and challenges for the future publication-title: Drugs R D doi: 10.1007/s40268-018-0230-3 – volume: 10 year: 2015 ident: CR41 article-title: Pain in Parkinson’s disease: A cross-sectional study of its prevalence, types, and relationship to depression and quality of life publication-title: PLoS One doi: 10.1371/journal.pone.0136541 – volume: 38 start-page: 1236 year: 2023 end-page: 1252 ident: CR13 article-title: Levodopa dose equivalency in Parkinson’s disease: Updated systematic review and proposals publication-title: Mov. Disord. doi: 10.1002/mds.29410 – volume: 38 start-page: 89 year: 2015 end-page: 103 ident: CR31 article-title: Effective delivery of apomorphine in the management of Parkinson disease: Practical considerations for clinicians and Parkinson nurses publication-title: Clin. Neuropharmacol. doi: 10.1097/WNF.0000000000000082 – volume: 2 start-page: 4 year: 2009 end-page: 9 ident: CR36 article-title: Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease publication-title: J. Mov. Disord. doi: 10.14802/jmd.09002 – volume: 120 start-page: 1305 year: 2013 end-page: 1320 ident: CR5 article-title: Motor and nonmotor complications in Parkinson’s disease: An argument for continuous drug delivery? publication-title: J. Neural Transm. (Vienna) doi: 10.1007/s00702-013-0981-5 – volume: 7 start-page: 1 year: 2021 end-page: 11 ident: CR30 article-title: Long-term effect of apomorphine infusion in advanced Parkinson’s disease: A real-life study publication-title: npj Parkinsons Dis. doi: 10.1038/s41531-021-00194-7 – volume: 33 start-page: 905 year: 2019 end-page: 918 ident: CR7 article-title: Apomorphine for Parkinson’s disease: Efficacy and safety of current and new formulations publication-title: CNS Drugs doi: 10.1007/s40263-019-00661-z – volume: 17 start-page: 939 year: 2018 end-page: 953 ident: CR3 article-title: Global, regional, and national burden of Parkinson’s disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30295-3 – volume: 22 start-page: 1901 year: 2007 end-page: 1911 ident: CR16 article-title: The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study publication-title: Mov. Disord. doi: 10.1002/mds.21596 – volume: 11 start-page: 524 year: 2020 ident: CR2 article-title: Genetic architecture of Parkinson’s disease in the Indian population: Harnessing genetic diversity to address critical gaps in Parkinson’s disease research publication-title: Front. Neurol. doi: 10.3389/fneur.2020.00524 – volume: 17 year: 1967 ident: CR12 article-title: Parkinsonism: Onset, progression, and mortality publication-title: Neurology doi: 10.1212/WNL.17.5.427 – volume: 4 start-page: 78 year: 2017 end-page: 83 ident: CR44 article-title: Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease publication-title: Mov. Disord. Clin. Pract. doi: 10.1002/mdc3.12350 – volume: 30 start-page: 510 year: 2015 end-page: 516 ident: CR49 article-title: EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease publication-title: Mov. Disord. doi: 10.1002/mds.26067 – year: 2023 ident: CR51 article-title: Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: The APOKADO study publication-title: J. Neural Transm. doi: 10.1007/s00702-023-02609-6 – volume: 64 start-page: 393 year: 2014 end-page: 394 ident: CR17 article-title: The Hospital Anxiety and Depression Scale publication-title: Occup. Med. doi: 10.1093/occmed/kqu024 – volume: 12 start-page: 805 year: 1997 end-page: 814 ident: CR15 article-title: The PDQ-8: Development and validation of a short-form Parkinson’s disease questionnaire publication-title: Psychol. Health doi: 10.1080/08870449708406741 – volume: 13 year: 2018 ident: CR28 article-title: Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: A systematic review publication-title: Cureus – volume: 3 start-page: 145 year: 2020 ident: CR9 article-title: Subcutaneous apomorphine in advanced Parkinson’s disease and its use in Indian population publication-title: Ann. Mov. Disord. doi: 10.4103/AOMD.AOMD_16_20 – volume: 82 start-page: 257 year: 1987 end-page: 258 ident: CR23 article-title: Aversion treatment of alcoholism: some reminiscences publication-title: Br. J. Addict. doi: 10.1111/j.1360-0443.1987.tb01479.x – volume: 33 start-page: S9 issue: Suppl 1 year: 2016 end-page: S12 ident: CR6 article-title: Apomorphine and levodopa in Parkinson’s disease: Two revolutionary drugs from the 1950’s publication-title: Parkinsonism Relat. Disord. doi: 10.1016/j.parkreldis.2016.12.004 – volume: 13 start-page: 78 year: 2019 end-page: 81 ident: CR18 article-title: Montreal Cognitive Assessment scale in patients with Parkinson Disease with normal scores in the Mini-Mental State Examination publication-title: Dement. Neuropsychol. doi: 10.1590/1980-57642018dn13-010008 – volume: 13 year: 2018 ident: CR43 article-title: The effects of a dopamine agonist (apomorphine) on experimental and spontaneous pain in patients with chronic radicular pain: A randomized, double-blind, placebo-controlled, cross-over study publication-title: PLoS One doi: 10.1371/journal.pone.0195287 – ident: CR32 – volume: 11 start-page: 680 year: 2021 ident: CR4 article-title: Parkinson’s disease: Personalized pathway of care for device-aided therapies (DAT) and the role of continuous objective monitoring (COM) using wearable sensors publication-title: J. Pers. Med. doi: 10.3390/jpm11070680 – volume: 9 start-page: 469 year: 2016 end-page: 479 ident: CR42 article-title: Pain management in patients with Parkinson’s disease: Challenges and solutions publication-title: J. Multidiscip. Healthc. doi: 10.2147/JMDH.S105857 – ident: CR10 – volume: 5 start-page: 45 year: 2019 end-page: 48 ident: CR19 article-title: Fatigue evaluated using the 16-item Parkinson Fatigue Scale (PFS-16) predicts Parkinson’s disease prognosis publication-title: Fujita Med. J. – volume: 34 start-page: 353 year: 2019 end-page: 365 ident: CR50 article-title: EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease publication-title: Mov. Disord. doi: 10.1002/mds.27626 – ident: CR27 – volume: 21 start-page: 1023 year: 2015 end-page: 1030 ident: CR8 article-title: Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease—Clinical practice recommendations publication-title: Parkinsonism Relat. Disord. doi: 10.1016/j.parkreldis.2015.06.012 – volume: 73 start-page: 629 year: 2002 end-page: 635 ident: CR20 article-title: The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.73.6.629 – volume: 40 start-page: 747 year: 2015 end-page: 773 ident: CR33 article-title: Parkinson’s disease and its management publication-title: P T – volume: 11 start-page: 295 year: 2002 end-page: 302 ident: CR24 article-title: Sublingual apomorphine for the treatment of erectile dysfunction publication-title: Expert Opin. Investig. Drugs doi: 10.1517/13543784.11.2.295 – volume: 33 start-page: S13 issue: Suppl 1 year: 2016 end-page: S21 ident: CR34 article-title: Apomorphine—Pharmacological properties and clinical trials in Parkinson’s disease publication-title: Parkinsonism Relat. Disord. doi: 10.1016/j.parkreldis.2016.12.003 – volume: 30 start-page: 1623 year: 2015 end-page: 1631 ident: CR21 article-title: King’s Parkinson’s disease pain scale, the first scale for pain in PD: An international validation publication-title: Mov. Disord. doi: 10.1002/mds.26270 – volume: 17 start-page: 749 year: 2018 end-page: 759 ident: CR29 article-title: Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): A multicentre, double-blind, randomised, placebo-controlled trial publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30239-4 – volume: 5 start-page: 235 year: 2006 end-page: 245 ident: CR35 article-title: Non-motor symptoms of Parkinson’s disease: Diagnosis and management publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(06)70373-8 – volume: 56 start-page: 251 year: 1951 end-page: 253 ident: CR25 article-title: Apomorphine in Parkinson’s disease publication-title: Trans. Am. Neurol. Assoc. – volume: 42 start-page: 2961 year: 2021 end-page: 2964 ident: CR48 article-title: Device-aided therapies for advanced Parkinson disease: Insights from an international survey publication-title: Neurol. Sci. doi: 10.1007/s10072-021-05106-4 – volume: 58 start-page: 1385 year: 2001 end-page: 1392 ident: CR46 article-title: A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events publication-title: Arch. Neurol. doi: 10.1001/archneur.58.9.1385 – volume: 1 start-page: 403 year: 1988 end-page: 406 ident: CR26 article-title: Subcutaneous apomorphine in parkinsonian on-off oscillations publication-title: Lancet doi: 10.1016/S0140-6736(88)91193-2 – volume: 11 year: 2021 ident: CR11 article-title: Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease publication-title: Brain Behav. doi: 10.1002/brb3.2086 – volume: 17 start-page: 455 year: 1869 end-page: 460 ident: CR22 article-title: III. Researches into the chemical constitution of the opium bases. Part I—On the action of hydrochloric acid on morphia publication-title: Proc. R. Soc. Lond. doi: 10.1098/rspl.1868.0094 – volume: 2 start-page: 1 year: 2020 end-page: 8 ident: CR40 article-title: An overview of pain in Parkinson’s disease publication-title: Clin. Parkinsonism Relat. Disord. doi: 10.1016/j.prdoa.2019.11.004 – volume: 162 start-page: 999 year: 2021 end-page: 1006 ident: CR38 article-title: Pain in the neurodegenerating brain: Insights into pharmacotherapy for Alzheimer disease and Parkinson disease publication-title: Pain doi: 10.1097/j.pain.0000000000002111 – volume: 8 start-page: 1 year: 2022 end-page: 7 ident: CR1 article-title: Incidence of Parkinson disease in North America publication-title: npj Parkinsons Dis. doi: 10.1038/s41531-022-00410-y – volume: 23 start-page: 2129 year: 2008 end-page: 2170 ident: CR14 article-title: Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results: MDS-UPDRS: Clinimetric Assessment publication-title: Mov. Disord. doi: 10.1002/mds.22340 – volume: 269 start-page: 1154 year: 2022 end-page: 1163 ident: CR37 article-title: Gastrointestinal dysfunction in Parkinson’s disease: Molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation publication-title: J. Neurol. doi: 10.1007/s00415-021-10567-w – volume: 8 start-page: 63 year: 2013 end-page: 68 ident: CR47 article-title: Domperidone in Parkinson’s disease: A perilous arrhythmogenic or the gold standard? publication-title: Curr. Drug Saf. doi: 10.2174/1574886311308010009 – volume: 3 start-page: 1 year: 2017 end-page: 6 ident: CR39 article-title: Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale publication-title: npj Parkinson’s Dis. – volume: 56 start-page: 251 year: 1951 ident: 46003_CR25 publication-title: Trans. Am. Neurol. Assoc. – volume: 12 start-page: 805 year: 1997 ident: 46003_CR15 publication-title: Psychol. Health doi: 10.1080/08870449708406741 – volume: 13 start-page: 78 year: 2019 ident: 46003_CR18 publication-title: Dement. Neuropsychol. doi: 10.1590/1980-57642018dn13-010008 – volume: 21 start-page: 1023 year: 2015 ident: 46003_CR8 publication-title: Parkinsonism Relat. Disord. doi: 10.1016/j.parkreldis.2015.06.012 – volume: 11 year: 2021 ident: 46003_CR11 publication-title: Brain Behav. doi: 10.1002/brb3.2086 – volume: 73 start-page: 629 year: 2002 ident: 46003_CR20 publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.73.6.629 – volume: 5 start-page: 45 year: 2019 ident: 46003_CR19 publication-title: Fujita Med. J. – volume: 2 start-page: 1 year: 2020 ident: 46003_CR40 publication-title: Clin. Parkinsonism Relat. Disord. doi: 10.1016/j.prdoa.2019.11.004 – volume: 33 start-page: S13 issue: Suppl 1 year: 2016 ident: 46003_CR34 publication-title: Parkinsonism Relat. Disord. doi: 10.1016/j.parkreldis.2016.12.003 – volume: 42 start-page: 2961 year: 2021 ident: 46003_CR48 publication-title: Neurol. Sci. doi: 10.1007/s10072-021-05106-4 – volume: 3 start-page: 145 year: 2020 ident: 46003_CR9 publication-title: Ann. Mov. Disord. doi: 10.4103/AOMD.AOMD_16_20 – volume: 11 start-page: 295 year: 2002 ident: 46003_CR24 publication-title: Expert Opin. Investig. Drugs doi: 10.1517/13543784.11.2.295 – volume: 18 start-page: 91 year: 2018 ident: 46003_CR45 publication-title: Drugs R D doi: 10.1007/s40268-018-0230-3 – volume: 8 start-page: 63 year: 2013 ident: 46003_CR47 publication-title: Curr. Drug Saf. doi: 10.2174/1574886311308010009 – volume: 34 start-page: 353 year: 2019 ident: 46003_CR50 publication-title: Mov. Disord. doi: 10.1002/mds.27626 – volume: 8 start-page: 1 year: 2022 ident: 46003_CR1 publication-title: npj Parkinsons Dis. doi: 10.1038/s41531-022-00410-y – volume: 22 start-page: 1901 year: 2007 ident: 46003_CR16 publication-title: Mov. Disord. doi: 10.1002/mds.21596 – volume: 64 start-page: 393 year: 2014 ident: 46003_CR17 publication-title: Occup. Med. doi: 10.1093/occmed/kqu024 – volume: 11 start-page: 524 year: 2020 ident: 46003_CR2 publication-title: Front. Neurol. doi: 10.3389/fneur.2020.00524 – volume: 17 start-page: 455 year: 1869 ident: 46003_CR22 publication-title: Proc. R. Soc. Lond. doi: 10.1098/rspl.1868.0094 – volume: 38 start-page: 89 year: 2015 ident: 46003_CR31 publication-title: Clin. Neuropharmacol. doi: 10.1097/WNF.0000000000000082 – volume: 4 start-page: 78 year: 2017 ident: 46003_CR44 publication-title: Mov. Disord. Clin. Pract. doi: 10.1002/mdc3.12350 – volume: 38 start-page: 1236 year: 2023 ident: 46003_CR13 publication-title: Mov. Disord. doi: 10.1002/mds.29410 – volume: 10 year: 2015 ident: 46003_CR41 publication-title: PLoS One doi: 10.1371/journal.pone.0136541 – volume: 33 start-page: S9 issue: Suppl 1 year: 2016 ident: 46003_CR6 publication-title: Parkinsonism Relat. Disord. doi: 10.1016/j.parkreldis.2016.12.004 – ident: 46003_CR32 doi: 10.1017/CBO9781107284210.006 – volume: 5 start-page: 235 year: 2006 ident: 46003_CR35 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(06)70373-8 – volume: 13 year: 2018 ident: 46003_CR43 publication-title: PLoS One doi: 10.1371/journal.pone.0195287 – year: 2023 ident: 46003_CR51 publication-title: J. Neural Transm. doi: 10.1007/s00702-023-02609-6 – volume: 30 start-page: 1623 year: 2015 ident: 46003_CR21 publication-title: Mov. Disord. doi: 10.1002/mds.26270 – ident: 46003_CR10 – volume: 23 start-page: 2129 year: 2008 ident: 46003_CR14 publication-title: Mov. Disord. doi: 10.1002/mds.22340 – volume: 58 start-page: 1385 year: 2001 ident: 46003_CR46 publication-title: Arch. Neurol. doi: 10.1001/archneur.58.9.1385 – volume: 17 start-page: 939 year: 2018 ident: 46003_CR3 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30295-3 – volume: 82 start-page: 257 year: 1987 ident: 46003_CR23 publication-title: Br. J. Addict. doi: 10.1111/j.1360-0443.1987.tb01479.x – volume: 40 start-page: 747 year: 2015 ident: 46003_CR33 publication-title: P T – volume: 13 year: 2018 ident: 46003_CR28 publication-title: Cureus – volume: 17 start-page: 749 year: 2018 ident: 46003_CR29 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30239-4 – volume: 30 start-page: 510 year: 2015 ident: 46003_CR49 publication-title: Mov. Disord. doi: 10.1002/mds.26067 – volume: 3 start-page: 1 year: 2017 ident: 46003_CR39 publication-title: npj Parkinson’s Dis. doi: 10.1038/s41531-016-0004-y – volume: 11 start-page: 680 year: 2021 ident: 46003_CR4 publication-title: J. Pers. Med. doi: 10.3390/jpm11070680 – volume: 162 start-page: 999 year: 2021 ident: 46003_CR38 publication-title: Pain doi: 10.1097/j.pain.0000000000002111 – volume: 9 start-page: 469 year: 2016 ident: 46003_CR42 publication-title: J. Multidiscip. Healthc. doi: 10.2147/JMDH.S105857 – volume: 7 start-page: 1 year: 2021 ident: 46003_CR30 publication-title: npj Parkinsons Dis. doi: 10.1038/s41531-021-00194-7 – volume: 120 start-page: 1305 year: 2013 ident: 46003_CR5 publication-title: J. Neural Transm. (Vienna) doi: 10.1007/s00702-013-0981-5 – volume: 2 start-page: 4 year: 2009 ident: 46003_CR36 publication-title: J. Mov. Disord. doi: 10.14802/jmd.09002 – volume: 33 start-page: 905 year: 2019 ident: 46003_CR7 publication-title: CNS Drugs doi: 10.1007/s40263-019-00661-z – volume: 17 year: 1967 ident: 46003_CR12 publication-title: Neurology doi: 10.1212/WNL.17.5.427 – volume: 1 start-page: 403 year: 1988 ident: 46003_CR26 publication-title: Lancet doi: 10.1016/S0140-6736(88)91193-2 – volume: 269 start-page: 1154 year: 2022 ident: 46003_CR37 publication-title: J. Neurol. doi: 10.1007/s00415-021-10567-w – ident: 46003_CR27 |
| SSID | ssj0000529419 |
| Score | 2.4320567 |
| Snippet | Advanced Parkinson’s Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually become... Advanced Parkinson's Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually become... Abstract Advanced Parkinson’s Disease (APD) is complicated by the emergence of motor and non-motor fluctuations, which are initially predictable and eventually... |
| SourceID | doaj pubmedcentral proquest crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 18681 |
| SubjectTerms | 631/378 692/617 Apomorphine Dopamine receptors Dyskinesia Fluctuations Humanities and Social Sciences Levodopa Movement disorders multidisciplinary Neurodegenerative diseases Parkinson's disease Quality of life Safety Science Science (multidisciplinary) Side effects |
| SummonAdditionalLinks | – databaseName: Science Database dbid: M2P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zi9UwFA46KvjiLlZHiSCoaJhmaZv6IuMyOKDXCy7MW0jSdBy4tte2V7h_wN9tTroMHXBefCtN2iY9a3JOvoPQkyxLtLBUEM5MTIRLSyLLwhDmcm6YjHMToJS-f8wWC3l0lC-HDbd2SKscdWJQ1EVtYY98j0kpwHeJ6ev1LwJVoyC6OpTQuIguec-GQkrXJ7ac9lggiiVoPpyVibnca729gjNljBORQlqWmNmjANs_8zXPZkqeCZcGK3Rw_X_HfwNdG_xPvN8zzE10wVW30JW-IuX2NvrzRZeu22JdFbirV67pYby3uC7xqq6OCWhyrNf1z9oTyHuo2HPoBnbc_AUeEwownKUOx8qetngIAb3y78SHFbAjDlmMBGbrGvxsf_mZHC7ePcdugl2-g74dvP_69gMZSjUQ6397R7gtrRdvkxQ0L6koKC-ZZgn3yz2TZ9plWZzE1HEtqLC5sNLZJDa5ibVLNPc64i7aqerK3UNYUu5Y5k23S72vlluTcmOptVSnuStZGSE6EkzZAcccymmsVIinc6l6IitPZBWIrESEXkzPrHsUj3N7vwE-mHoCAne4UTfHahBoJaXNNBRbK_wiUztj4qR0VBgNEGpcswjtjnygBrXQqlMmiNDjqdkLNERpdOXqTeiTMK9aUxkhOeO-2YDmLdXJjwANDgt87_JlEXo5Murp1_894_vnD_YBuspAZILJ3kU7XbNxD9Fl-7s7aZtHQeb-AjxqNMA priority: 102 providerName: ProQuest |
| Title | Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience |
| URI | https://link.springer.com/article/10.1038/s41598-023-46003-4 https://www.proquest.com/docview/2884507101 https://www.proquest.com/docview/2885204068 https://pubmed.ncbi.nlm.nih.gov/PMC10618227 https://doaj.org/article/88c7ace03d014aebb05fe14ba30553a2 |
| Volume | 13 |
| WOSCitedRecordID | wos001123935800094&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database (ProQuest) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA96p-CL-InVc4kgqGi4fLVJfLvTO1zw1uIX61NI0lQP1vbY7Qr7D_h3m6Td9fZAffFlKE3aJpmZzKSZ_AaAx0LkhjvCEaMWI-6LGsm6soh6xSyVWNkEpfT5rZhM5HSqynOpvmJMWA8P3A_cvpROmJjUqgrOvPHW4rz2hFsToaqYSbMvFurcYqpH9aaKEzWcksFM7i-CpYqnyShDvIgBWXzLEiXA_i0v82KM5IWN0mR_jm-A64PjCA_6Bt8El3xzC1ztU0muboOfH0ztuxU0TQW7dubnPf72CrY1nLXNVxSnYGjO2u9tGNngWsIgWsv4qyxcwHUkAIyHoNN5sCcLOOzdvAzvhOMmyhFM4YcoNtbP4dOD8h0aT14_g36Dl3wHfDo--vjqDRpyLCCXE9kh5moX9NLmFVE14RVhNTU0Z2GdZpUwXgicY-KZ4YQ7xZ30LsdWWWx8blhQ7rtgp2kbfw9ASZinIthcXwQnSzlbMOuIc8QUyte0zgBZj7d2AwB5zIMx02kjnEnd80gHHunEI80z8HzzzFkPv_HX2oeRjZuaETo73QgCpQeB0v8SqAzsrYVAD_q80FRKHj1nTDLwaFMcNDFur5jGt8tUJ6dhTixkBuSW8Gw1aLukOf2WML3jyjz4aiIDL9Zy9vvrf-7x_f_R4wfgGo16kSzyHtjp5kv_EFxxP7rTxXwELoupSFSOwO7h0aR8P0rKFugJLSMVge6W45Pyyy_oTS5j |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamAYIX7ojAACOBAIG1-JLEQUJoMKZVK6USG9qbsR1nTCpJ6QXUP8DP4Tfi4ySdOom97YG3KnHSxPnOxT7nfAehJ1mWaGGpIJyZmAiXlkSWhSHM5dwwGecmUCl96WeDgTw8zIdr6E9XCwNplZ1ODIq6qC3skW8yKQX4LjF9O_5BoGsURFe7FhoNLPbc4pdfsk3f9Lb9933K2M6H_fe7pO0qQGxC5YxwW1qPRJMUNC-pKCgvmWYJ9ysTk2faZVmcxNRxLaiwubDS2SQ2uYm1SzTPgHzJq_wLApjFIFWQDZd7OhA1EzRva3NiLjen3j5CDRvjRKSQBiZW7F9oE7Di257OzDwVng1Wb-fa_zZf19HV1r_GW41A3EBrrrqJLjUdNxe30O_PunSzBdZVgWf1yE0amvIFrks8qqsjApYK63H9vfYA9B449hI4hx1F_wN3CRMYasVD2dyzKW5DXK_9PXGvAnHDIUuTwOy6CX6-NfxEeoPtF9gtaaVvo4NzmYQ7aL2qK3cXYUm5Y5l3TVzqfdHcmpQbS62lOs1dycoI0Q4gyrY87dAuZKRCvgCXqgGV8qBSAVRKROjl8ppxw1Jy5uh3gLvlSGAYDwfqyZFqFZaS0mYamskVfhGtnTFxUjoqjAaKOK5ZhDY63KlW7U3VCegi9Hh52issiELpytXzMCZh3nSkMkJyBe0rD7R6pjr-FqjPYQPDu7RZhF51gnHy7_9-43tnP-wjdHl3_2Nf9XuDvfvoCgNxDe7JBlqfTebuAbpof86Op5OHQd4x-nreAvMXF5GQfA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamDhAv3NECA4wEAgRW40sSBwmhQamoNkolBhpPnu3YY1JJSi-g_gF-FL8O20k6dRJ72wNvVeKkifOdcz773AB4lGWJZBozRImKETOpRdwWChGTU0V4nKtQSunLXjYc8oODfLQB_rS5MD6sstWJQVEXlfZ75F3COfPcJcZd24RFjHr915MfyHeQ8p7Wtp1GDZFds_zllm-zV4Oe-9aPCem_23_7HjUdBpBOMJ8jqq12qFRJgXOLWYGpJZIk1K1SVJ5Jk2VxEmNDJcNM50xzo5NY5SqWJpE084WYnPrfdJSckQ7YHA0-jL6udni8D43hvMnUiSnvzpy19BlthCKW-qAwtmYNQ9OANaZ7Ok7zlLM22MD-1f959q6BKw3zhju1qFwHG6a8AS7WvTiXN8HvT9Ka-RLKsoDzamymdQHzJawsHFflEfI2DMpJ9b1y0HTcHDrZXPi9RvcDtqEU0GeRh4S6JzPYOL9eunvCQekFEYb4TeRn2kzh053RRzQY9p5Bsyo4fQt8PpdJuA06ZVWaLQA5poZkjrSY1LHUXKuUKo21xjLNjSU2ArgFi9BNBXffSGQsQiQB5aIGmHAAEwFggkXg-eqaSV2_5MzRbzwGVyN97fFwoJoeiUaVCc51Jn2bucItr6VRKk6swUxJXzyOShKB7RaDolGIM3ECwAg8XJ12qsz7p2RpqkUYkxBnVFIeAb6G_LUHWj9THn8LRdH91oYju1kEXrRCcvLv_37jO2c_7ANwycmJ2BsMd--Cy8RLbuAt26Azny7MPXBB_5wfz6b3G-GH4PC8JeYv1DOaxQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+tolerability+of+long-term+apomorphine+infusion+in+advanced+Parkinson%27s+disease%3A+an+Indian+multi-center+%28APO-IND%29+experience&rft.jtitle=Scientific+reports&rft.au=Metta%2C+Vinod&rft.au=Dhamija%2C+Rajinder+K&rft.au=Batzu%2C+Lucia&rft.au=Mrudula%2C+Rukmini&rft.date=2023-10-31&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=13&rft.issue=1&rft.spage=18681&rft_id=info:doi/10.1038%2Fs41598-023-46003-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |